ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

Xiao, Minglu; Xie, Luoyingzi; Cao, Guoshuai; Lei, Shun; Wang, Pengcheng; Wei, Zhengping; Luo, Yuan; Fang, Jingyi; Yang, Xingxing; Huang, Qizhao; Xu, Lifan; Guo, Junyi; Wen, Shuqiong; Wang, Zhiming; Wu, Qing; Tang, Jianfang; Wang, Lisha; Chen, Xiangyu; Chen, Cheng; Zhang, Yanyan; Yao, Wei; Ye, Jianqiang*; He, Ran*; Huang, Jun*; Ye, Lilin*华中科技大学; 南方医科大学; 中山大学; 中国科学院研究生院
Journal for ImmunoTherapy of Cancer2022-5DOI: 10.1136/jitc-2021-004022
7被引6阅读
引用收藏
分享

摘要

Background Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8(+) T cells. Paradoxically, continuous T cell receptor (TCR) stimulation from tumor-derived CD8(+) T-cell epitopes can drive the functional exhaustion of tumor-specific CD8(+) T cells. Tumor-specific type-I helper CD4(+) T (T(H)1) cells play an important role in the population maintenance and cytotoxic function of exhausted tumor-specific CD8(+) T cells in the tumor microenvironment. Nonetheless, whether the vaccination strategy targeting MHC-II-restricted CD4(+) T-cell epitopes to induce tumor-specific T(H)1 responses can confer effective antitumor immunity to restrain tumor growth is not well studied. Here, we developed a heterologous prime-boost vaccination strategy to effectively induce tumor-specific T(H)1 cells and evaluated its antitumor efficacy and its capacity to potentiate PD-1/PD-L1 immunotherapy. Methods Listeria monocytogenes vector and influenza A virus (PR8 strain) vector stably expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein-specific I-A(b)-restricted CD4(+) T cell epitope (GP(61-80)) or ovalbumin-specific CD4(+) T cell epitope (OVA(323-339)) were constructed and evaluated their efficacy against mouse models of melanoma and colorectal adenocarcinoma expressing lymphocytic choriomeningitis virus glycoprotein and ovalbumin. The impact of CD4(+) T cell epitope-based heterologous prime-boost vaccination was detected by flow-cytometer, single-cell RNA sequencing and single-cell TCR sequencing. Results CD4(+) T cell epitope-based heterologous prime-boost vaccination efficiently suppressed both mouse melanoma and colorectal adenocarcinoma. This vaccination primarily induced tumor-specific T(H)1 response, which in turn enhanced the expansion, effector function and clonal breadth of tumor-specific CD8(+) T cells. Furthermore, this vaccination strategy synergized PD-L1 blockade mediated tumor suppression. Notably, prime-boost vaccination extended the duration of PD-L1 blockade induced antitumor effects by preventing the re-exhaustion of tumor-specific CD8(+) T cells. Conclusion CD4(+) T cell epitope-based heterologous prime-boost vaccination elicited potent both tumor-specific T(H)1 and CTL response, leading to the efficient tumor control. This strategy can also potentiate PD-1/PD-L1 immune checkpoint blockade (ICB) against cancer.

学科与关键词

关键词
VaccinationCD4-Positive T-LymphocytesImmunotherapyCD8-Positive T-LymphocytesImmunization
相关
加载中…
  • Tumor-Specific CD4+ T Cells Restrain Established Metastatic Melanoma by Developing Into Cytotoxic CD4- T Cells
    Liu, Qiao*; Wang, Lisha; Lin, Huayu; Wang, Zhiming; Wu, Jialin; Guo, Junyi; Wen, Shuqiong; Ran, Ling; Yue, Zhengliang; Su, Xingxing; Wu, Qing; Tang, Jianfang; Li, Zhirong; Hu, Li; Xu, Lifan; Ye, Lilin*; Huang, Qizhao*Frontiers in Immunology, 2022, 13: 875718.被引 6
  • The primordial differentiation of tumor-specific memory CD8+T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
    Huang, Qizhao; Wu, Xia; Wang, Zhiming; Chen, Xiangyu; Wang, Lisha; Lu, Yijun; Xiong, Dan; Liu, Qiao; Tian, Yuhan; Lin, Huayu; Guo, Junyi; Wen, Shuqiong; Dong, Wei; Yang, Xiaofan; Yuan, Yuchen; Yue, Zhengliang; Lei, Shun; Wu, Qing; Ran, Ling; Xie, Luoyingzi; Wang, Yifei; Gao, Leiqiong; Tian, Qin; Zhou, Xinyuan; Sun, Beicheng*; Xu, Lifan*; Tang, Zhonghui*; Ye, Lilin*Cell, 2022, 185(22): 4049-+.被引 61
  • PD-1/PD-L1 blockade restores tumor-induced COVID-19 vaccine bluntness
    Chen, Xiangyu; Lin, Yao; Yue, Shuai; Yang, Yang; Yang, Xiaofan; He, Junjian; Gao, Leiqiong; Li, Zhirong; Hu, Li; Tang, Jianfang; Wang, Yifei; Tian, Qin; Hao, Yaxing; Xu, Lifan; Huang, Qizhao; Cao, Yingjiao*; Ye, Lilin*Vaccine, 2023, 41(34): 4986-4995.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal for ImmunoTherapy of Cancer
发表日期
2022-05
卷期
第 10 卷, 第 5 期
页码
e004022
DOI
10.1136/jitc-2021-004022
期刊等级
2区
成果收录
SCIE

作者

  • X

    Xiao, Minglu (第一作者)

    third mil med univ · chinese peoples liberat army gen hosp

  • X

    Xie, Luoyingzi

    third mil med univ

查看全部 25 位作者收起作者
  • C

    Cao, Guoshuai

  • L

    Lei, Shun

    third mil med univ

  • W

    Wang, Pengcheng

  • W

    Wei, Zhengping

    third mil med univ

  • L

    Luo, Yuan

    huazhong univ sci & technol

  • F

    Fang, Jingyi

    third mil med univ

  • Y

    Yang, Xingxing

    2 · third mil med univ

  • H

    Huang, Qizhao

    southern med univ

  • X

    Xu, Lifan

    third mil med univ

  • G

    Guo, Junyi

    sun yat sen univ

  • W

    Wen, Shuqiong

    sun yat sen univ

  • W

    Wang, Zhiming

    third mil med univ

  • W

    Wu, Qing

    third mil med univ

  • T

    Tang, Jianfang

    third mil med univ

  • W

    Wang, Lisha

    third mil med univ

  • C

    Chen, Xiangyu

    southern med univ

  • C

    Chen, Cheng

    third mil med univ

  • Z

    Zhang, Yanyan

    univ chinese acad sci

  • Y

    Yao, Wei

    third mil med univ

  • Y

    Ye, Jianqiang (通讯)

    yangzhou univ

  • H

    He, Ran (通讯)

    huazhong univ sci & technol

  • H

    Huang, Jun (通讯)

  • Y

    Ye, Lilin (通讯)

    third mil med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417